Table 1 IVGTT set characteristics. (Man-Whitney or chi square significances for the difference between IG9 and IG16 sets are shown in superscript against the the IG9 set values).

From: The importance of intravenous glucose tolerance test glucose stimulus for the evaluation of insulin secretion

 

IG16 set (n = 2,951 IVGTTs for 1,929 participants)

IG9 set (n = 855 IVGTTs for 499 participants)

women, % (n)

61 (1803)

88 (751)<0.001

Age (years), median (range. IG9 n = 645)

53.1 (18.9, 82.2)

31.0 (12.8, 65.5)<0.001

Weight ≥ 120%IBW % (n)

13 (369)

24 (202)<0.001

Excluded diagnoses/medications % (n)

none

31 (1020)

19 (160)<0.001

excluded diagnoses

37 (1088)

54 (465)<0.001

excluded medications

44 1289)

57 (489)<0.001

excluded diagnoses and medications

15 (445)

30 (258)<0.001

Anthropometry, median (range)

weight (kg)

67.7 (39.5, 133.0)

62.5 (31.6, 109.6)<0.001

body surface area (m2)

1.77 (1.30, 2.61)

1.70 (1.15, 2.39)<0.001

% ideal body weight

106 (68, 192)

103 (59, 197)0.03

body mass index (kg/m2)

24.2 (15.8, 43.0)

23.1 (13.9, 45.3)<0.001

fat-free mass (kg, IG9 n = 645)

45.8 (31.0, 88.5)

43.9 (32.7, 79.0)<0.001

height (cm)

167 (145, 197)

163 (142, 200)<0.001

IVGTT. median (range)

mean fasting glucose (mmol/L)

5.08 (3.81, 6.95)

4.75 (2.78, 6.97)<0.001

glucose load (g)

33.9 (19.8, 52.5)

31.3 (15.8, 54.8)<0.001

ΔG0 (mmol/L)

15.5 (8.2, 22.9)

15.4 (7.9, 27.2)0.08

gVOL (L)

12.1 (6.8, 20.0)

11.5 (4.3, 20.4)<0.001

AIRg (pmol/L.min, IG9 n = 30)

3160 (11, 26,109)

3195 (114, 15,502)0.8

Si (/min/pmol/L)

0.51 (0.05, 4.38)

0.35 (0.02, 3.45)<0.001

Sg (/min)

1.56 (0.24, 6.31)

1.91 (0.33, 6.74)<0.001